Monitoring people at risk of multiple myeloma.
UnifAI Technology's Digital Reader is being used to support a University of Birmingham project developing a lateral flow test to monitor people with MGUS (monoclonal gammopathy of unknown significance), a condition that can precede the blood cancer multiple myeloma.
- Status
- Research collaboration
- Partner
- University of Birmingham
- Focus
- MGUS monitoring and digital test interpretation
Towards simpler, more frequent monitoring
People with MGUS need regular monitoring for changes that could indicate progression to multiple myeloma. Current monitoring involves a blood sample taken in a clinical setting and sent to a laboratory, creating practical demands for patients and healthcare services.
The Birmingham project is developing a lateral flow test to monitor monoclonal protein levels. The aim is a simpler, lower-cost route that could make more frequent checks practical. Digital Reader supports consistent interpretation and a connected result that can be reviewed alongside the wider clinical picture.